Privacy Policy

Regenerative Pain Solutions (Anesthesia Specialists, P.A.) is sensitive to your privacy concerns on the Internet. We are committed to providing you with the most useful and reliable information to help you better understand our regenerative pain solutions.

To deliver an experience that meets your individual needs and, at the same time, ensures your privacy is protected, we have established the following privacy principles, as we believe it is important for you to know how we treat the information you provide to us.

The information obtained through https://regenerativepainsolutions.com/ about individual visitors is information provided voluntarily by visitors. When personal information is needed to offer you additional information, you will be explicitly informed of the need for that information.

This website’s newsletter registration and donation forms require visitors to provide us with contact and demographic information. The contact information is used to keep our donors informed about new information, features and events.

Only aggregated anonymous data of our users as a group (usage habits, demographic, survey, poll data) will be used for research, to provide our visitors with the highest quality of service and to provide our supporters with information about our visitors; no identifiable data will be shared at any time.

In some instances, if you send a question or feedback to us by email, we may request or require additional or specific personal information so we can provide you with a personal response. If you choose to supply this information, we will use it only for the specific purposes by which you supply it.

Occasionally, we may request material we can publish, such as visitors’ personal stories and Dear Doctor letters sent to us. To participate, you may be required to provide us with your identity and, in some cases, agree to have it publicly associated with your submission on our site. Participation rules will be highlighted on relevant pages and will vary. Your participation will always be voluntary. We will not release your name, street address, telephone number or email address to anyone without your expressed consent. We will not sell or provide access to your personal identification data to advertisers or marketers.

In regard to links to other websites, Regenerative Pain Solutions is not responsible for the privacy practices or the content of those websites. If you provide any information on your own or directly to any other sites you encounter on the Internet outside regenerativepainsolutions.com, different rules may apply to their use or disclosure of the personal information you share with them. We encourage you to investigate and ask questions before disclosing your information.

Note: This Privacy Policy may be updated from time to time; notice of changes will be highlighted. We hope our Privacy Policy clarifies our procedures in regard to your personal information. If you have any concerns or questions about any aspect of this policy or have any suggestions as to how we may better serve you, please send contact us by filling out the contact form on our site. We welcome your feedback, as we want you to be assured your privacy is securely protected.

Discover the science behind our success!

Regenerative Pain Solutions proudly uses Ggevityy products.

Book An Appointment

To learn more about our restorative therapies and whether or not you are a candidate, please fill the calendar below to book an appointment. We believe in personalized care because each individual is unique.

Mesenchymal stem cells (MSCs) are undifferentiated cells with a high proliferation capacity and mesodermal differentiation potential [1]. They are an important source of stem cells for damaged tissue regeneration in clinical applications. Although bone marrow (BM) has conventionally been used as the major source of pluripotent MSCs, BM collection requires a highly invasive procedure. Furthermore, with increasing age, the number, differentiation potential, and lifespan of MSCs from BM decrease [2]. Therefore, the umbilical cord and adipose tissue (AD) are used as alternative sources of MSCs [2]. Umbilical cord-derived stem cells originating in Wharton’s jelly (WJ) are called Wharton’s jelly mesenchymal stem cells (WJ-MSCs). They form a class of stem cells with a high differentiation potential, an immuno-privileged status, and easy access for collection, raising no legal or ethical issues. WJ-MSCs exhibit several features of embryonic stem cells, such as a short doubling time and potent expansion capacity, with only a few differences [3].

Mesenchymal stem cells (MSCs) are undifferentiated cells with a high proliferation capacity and mesodermal differentiation potential [1]. They are an important source of stem cells for damaged tissue regeneration in clinical applications. Although bone marrow (BM) has conventionally been used as the major source of pluripotent MSCs, BM collection requires a highly invasive procedure. Furthermore, with increasing age, the number, differentiation potential, and lifespan of MSCs from BM decrease [2]. Therefore, the umbilical cord and adipose tissue (AD) are used as alternative sources of MSCs [2]. Umbilical cord-derived stem cells originating in Wharton’s jelly (WJ) are called Wharton’s jelly mesenchymal stem cells (WJ-MSCs). They form a class of stem cells with a high differentiation potential, an immuno-privileged status, and easy access for collection, raising no legal or ethical issues. WJ-MSCs exhibit several features of embryonic stem cells, such as a short doubling time and potent expansion capacity, with only a few differences [3].
MSCs reside primarily in the bone marrow, where they were first characterized; nevertheless, they have a broad post-natal organ distribution (Friedenstein et al., 1970). MSCs have been isolated from different adult and fetal tissues (Uder et al., 2018). The adult tissues include adipose tissue, skeletal muscle, bone marrow, molar teeth/dental pulp, synovium/synovial fluid, skin, hematopoietic supportive stroma, and others (da Silva Meirelles et al., 2006). The fetal tissues include peripheral and umbilical cord blood, umbilical cord stroma or tissue, placenta, amniotic fluid, endometrium (da Silva Meirelles et al., 2006; Jiang et al., 2011). Although, MSCs share common characteristics including the expression of common cell surface markers (CD105, CD73 and CD90) and multipotency capacity to differentiate into osteoblasts, chondrocytes, or adipocytes (Carvalho et al., 2011; Ghaneialvar et al., 2018), they have different expression profiles and properties.
There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However, limitations include in vivo instability, reliance on biocompatible and robust carriers and restricted application procedures (local and direct). The aim of this paper is therefore to critically review the current literature surrounding the use of BPC 157, as a feasible therapy for healing and functional restoration of soft tissue damage, with a focus on tendon, ligament and skeletal muscle healing. Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues. However, to date, the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans. Further, over the past two decades, only a handful of research groups have performed in-depth studies regarding this peptide. Despite this, it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments. Moreover, skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of BPC 157, although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical realisation.

Book An Appointment


Book An Appointment

To learn more about our restorative therapies and whether or not you are a candidate, please fill the calendar below to book an appointment. We believe in personalized care because each individual is unique.

About Us

Ben Campbell: A Journey to Pioneering Regenerative Pain Solutions

For decades, Ben Campbell dedicated his career to enhancing patient comfort and effective pain management. His journey began in the late 1980s as a nurse anesthesiologist, where he tirelessly sought to improve pain relief techniques post-anesthesia. He explored regional anesthetics, spinals, epidurals, and individual nerve blocks, constantly refining his methods to ensure patients woke up pain-free and comfortable.

In his early days, Campbell was among the pioneers introducing epidural infusions for labor, providing consistent pain relief throughout labor rather than short-term single doses. He embraced ultrasound technology, teaching himself to use it for more precise nerve blocks, and shared knowledge with peers through courses and seminars. This innovation allowed him to perform anesthesia without relying on narcotics, leading to faster patient recovery and greater satisfaction.

Driven by a desire to prevent patients from needing surgery, he pursued a fellowship in chronic pain management. Transitioning from anesthesiology, he established a practice focused on comprehensive pain relief. However, he realized that traditional methods, such as steroid injections and nerve burning, provided only temporary relief and potentially harmful long-term effects.

Frustrated by the limitations of conventional treatments, Campbell explored restorative medicine as a path to lasting healing. This shift was inspired by a profound insight: rather than masking pain or using destructive techniques, why not promote healing at the source? Through extensive research, training, and practical application, he began incorporating restorative therapies into his practice, eventually dedicating himself entirely to this innovative approach.

Today, at Regenerative Pain Solutions, Ben Campbell is committed to treating the underlying causes of pain, helping patients achieve long-term wellness. Although insurance coverage for restorative treatments is limited, he strives to make these therapies accessible, often providing discounts to ensure more patients can benefit. Campbell’s journey from traditional pain management to restorative medicine embodies his unwavering dedication to improving patient care and outcomes.

Call Now Button